Table of Contents
Chapter 1. Global Monoclonal Antibody Therapeutics Market Executive Summary
1.1. Global Monoclonal Antibody Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Source
1.3.2. By Therapy Area
1.3.3. By Route of Administration
1.3.4. By Production Method
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Monoclonal Antibody Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Monoclonal Antibody Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Advancements in Biotechnology and Genetic Engineering
3.1.3. Rising Investment in Healthcare and Pharmaceutical R&D
3.2. Market Challenges
3.2.1. High Cost of Production and Treatment
3.2.2. Stringent Regulatory Requirements
3.3. Market Opportunities
3.3.1. Development of Novel Monoclonal Antibodies
3.3.2. Advances in Personalized Medicine and Companion Diagnostics
Chapter 4. Global Monoclonal Antibody Therapeutics Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by Source 2022-2032
5.1. Segment Dashboard
5.2. Global Monoclonal Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion/Billion)
5.2.1. Human
5.2.2. Humanized
5.2.3. Chimeric
5.2.4. Other Sources
Chapter 6. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by Therapy Area 2022-2032
6.1. Segment Dashboard
6.2. Global Monoclonal Antibody Therapeutics Market: Therapy Area Revenue Trend Analysis, 2022 & 2032 (USD Billion/Billion)
6.2.1. Autoimmune & Inflammatory Disorders
6.2.2. Oncology
6.2.3. Hematology
6.2.4. Ophthalmology
6.2.5. Other Therapy Areas
Chapter 7. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by Route of Administration 2022-2032
7.1. Segment Dashboard
7.2. Global Monoclonal Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion/Billion)
7.2.1. Intravenous
7.2.2. Subcutaneous
7.2.3. Other Route of Administrations
Chapter 8. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by Production Method 2022-2032
8.1. Segment Dashboard
8.2. Global Monoclonal Antibody Therapeutics Market: Production Method Revenue Trend Analysis, 2022 & 2032 (USD Billion/Billion)
8.2.1. In-Vitro
8.2.2. In-Vivo
Chapter 9. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by End User 2022-2032
9.1. Segment Dashboard
9.2. Global Monoclonal Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion/Billion)
9.2.1. Hospitals
9.2.2. Long-term Care Facilities
9.2.3. Other End Users
Chapter 10. Global Monoclonal Antibody Therapeutics Market Size & Forecasts by Region 2022-2032
10.1. North America Monoclonal Antibody Therapeutics Market
10.1.1. U.S. Monoclonal Antibody Therapeutics Market
10.1.1.1. Source breakdown size & forecasts, 2022-2032
10.1.1.2. Therapy Area breakdown size & forecasts, 2022-2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.4. Production Method breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Monoclonal Antibody Therapeutics Market
10.2. Europe Monoclonal Antibody Therapeutics Market
10.2.1. U.K. Monoclonal Antibody Therapeutics Market
10.2.2. Germany Monoclonal Antibody Therapeutics Market
10.2.3. France Monoclonal Antibody Therapeutics Market
10.2.4. Spain Monoclonal Antibody Therapeutics Market
10.2.5. Italy Monoclonal Antibody Therapeutics Market
10.2.6. Rest of Europe Monoclonal Antibody Therapeutics Market
10.3. Asia-Pacific Monoclonal Antibody Therapeutics Market
10.3.1. China Monoclonal Antibody Therapeutics Market
10.3.2. India Monoclonal Antibody Therapeutics Market
10.3.3. Japan Monoclonal Antibody Therapeutics Market
10.3.4. Australia Monoclonal Antibody Therapeutics Market
10.3.5. South Korea Monoclonal Antibody Therapeutics Market
10.3.6. Rest of Asia Pacific Monoclonal Antibody Therapeutics Market
10.4. Latin America Monoclonal Antibody Therapeutics Market
10.4.1. Brazil Monoclonal Antibody Therapeutics Market
10.4.2. Mexico Monoclonal Antibody Therapeutics Market
10.4.3. Rest of Latin America Monoclonal Antibody Therapeutics Market
10.5. Middle East & Africa Monoclonal Antibody Therapeutics Market
10.5.1. Saudi Arabia Monoclonal Antibody Therapeutics Market
10.5.2. South Africa Monoclonal Antibody Therapeutics Market
10.5.3. Rest of Middle East & Africa Monoclonal Antibody Therapeutics Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Abbvie Inc
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Amgen Inc.
11.3.3. AstraZeneca
11.3.4. Biogen
11.3.5. Bristol Myers Squibb Company
11.3.6. Eli Lilly and Company
11.3.7. F. Hoffmann-La Roche Ltd
11.3.8. Johnson & Johnson Services, Inc
11.3.9. Merck & Co., Inc
11.3.10. Novartis AG
11.3.11. Sanofi
11.3.12. UCB S.A
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes